Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

USA - NASDAQ:LYEL - US55083R2031 - Common Stock

15.87 USD
-0.68 (-4.11%)
Last: 10/2/2025, 1:58:01 PM
Fundamental Rating

2

Taking everything into account, LYEL scores 2 out of 10 in our fundamental rating. LYEL was compared to 536 industry peers in the Biotechnology industry. LYEL has a great financial health rating, but its profitability evaluates not so good. LYEL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LYEL has reported negative net income.
LYEL had a negative operating cash flow in the past year.
In the past 5 years LYEL always reported negative net income.
LYEL had a negative operating cash flow in each of the past 5 years.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -85.98%, LYEL is not doing good in the industry: 71.64% of the companies in the same industry are doing better.
With a Return On Equity value of -110.86%, LYEL perfoms like the industry average, outperforming 42.91% of the companies in the same industry.
Industry RankSector Rank
ROA -85.98%
ROE -110.86%
ROIC N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LYEL has more shares outstanding
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

LYEL has an Altman-Z score of -4.10. This is a bad value and indicates that LYEL is not financially healthy and even has some risk of bankruptcy.
LYEL has a Altman-Z score of -4.10. This is comparable to the rest of the industry: LYEL outperforms 43.47% of its industry peers.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.1
ROIC/WACCN/A
WACC10.03%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 7.65 indicates that LYEL has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.65, LYEL is doing good in the industry, outperforming 72.01% of the companies in the same industry.
A Quick Ratio of 7.65 indicates that LYEL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.65, LYEL is doing good in the industry, outperforming 72.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

LYEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.47%, which is quite good.
Looking at the last year, LYEL shows a small growth in Revenue. The Revenue has grown by 1.69% in the last year.
The Revenue for LYEL have been decreasing by -37.89% on average. This is quite bad
EPS 1Y (TTM)12.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-38.46%

3.2 Future

LYEL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.58% yearly.
LYEL is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y23.08%
EPS Next 2Y10.42%
EPS Next 3Y8.58%
EPS Next 5YN/A
Revenue Next Year-36.36%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LYEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.42%
EPS Next 3Y8.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (10/2/2025, 1:58:01 PM)

15.87

-0.68 (-4.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-07 2025-11-07
Inst Owners40.92%
Inst Owner Change-89.36%
Ins Owners0.58%
Ins Owner Change1.36%
Market Cap304.86M
Analysts42.86
Price Target11.22 (-29.3%)
Short Float %1.2%
Short Ratio2.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.26%
Min EPS beat(2)3.59%
Max EPS beat(2)20.93%
EPS beat(4)3
Avg EPS beat(4)6.46%
Min EPS beat(4)-15.34%
Max EPS beat(4)20.93%
EPS beat(8)6
Avg EPS beat(8)9.38%
EPS beat(12)10
Avg EPS beat(12)19.12%
EPS beat(16)13
Avg EPS beat(16)18.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-31.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.52%
EPS NY rev (1m)26.72%
EPS NY rev (3m)15.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)31.21%
Revenue NY rev (3m)-40.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5081.05
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-13.83
EYN/A
EPS(NY)-12.34
Fwd EYN/A
FCF(TTM)-10.59
FCFYN/A
OCF(TTM)-8.93
OCFYN/A
SpS0
BVpS15.56
TBVpS15.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.98%
ROE -110.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 195.7%
Cap/Sales 53105%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z -4.1
F-Score3
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)103.35%
Cap/Depr(5y)398.19%
Cap/Sales(3y)18080.8%
Cap/Sales(5y)11104.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
EPS Next Y23.08%
EPS Next 2Y10.42%
EPS Next 3Y8.58%
EPS Next 5YN/A
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-38.46%
Revenue Next Year-36.36%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y4.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.14%
EBIT Next 3Y-13.58%
EBIT Next 5YN/A
FCF growth 1Y-17.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.37%
OCF growth 3YN/A
OCF growth 5YN/A